When people think about weight loss and GLP-1 medications, they usually picture a syringe. That could soon change. In May 2026, the EMA’s Committee for Medicinal Products for Human Use (CHMP) gave the green light to the first high-dose oral version of semaglutide for weight loss, known under the brand name Wegovy®, this time as a tablet instead of an injection.
The medication has been on the market in the USA since January 2026, and its launch in Germany is expected for the summer. What distinguishes the tablet from the injection technically, what studies show about its efficacy, which side effects are possible, and who it is actually suitable for—this article provides a well-founded overview.
Why a tablet is more challenging than a syringe
Semaglutide is a peptide drug; a small protein molecule. Peptides are largely broken down by stomach acid and digestive enzymes in the gut before they can even enter the bloodstream. This is exactly why GLP-1 drugs have had to be injected until now: An injection bypasses the digestive tract entirely.
The new tablet solves this problem with an excipient called SNAC, which temporarily makes the stomach lining more permeable, allowing a small portion of the active ingredient to pass through before it is broken down.
The drawback: Only a fraction of the amount taken is actually absorbed—well under 1 percent. Therefore, at 25 mg, the tablet contains a much higher amount of the active ingredient than the injection (2.4 mg) in order to achieve a comparable effect in the body.
How taking the weight loss pill works
The instructions for use are much stricter than for the injection:
- On an empty stomach in the morning, immediately after getting up
- At most a small sip of water (approx. 120 ml), no other liquid
- At least 30 minutes before the first meal, coffee, or other medications
- Swallow the tablet whole, do not split, chew, or crush it
If this window is not observed, the absorption of the active ingredient decreases further and the effect may diminish. This is the central difference from the injection, which works independently of meals and time of day and only needs to be administered once a week.
Efficacy of the weight loss pill: What the studies show
The approval is primarily based on the OASIS-4 study program. The most important results after 64 weeks of treatment:
- Average weight loss: 13.6 percent across all participants
- With consistent use (adherence to therapy) up to 16.6 percent
- About one in three people lost 20 percent or more of their initial weight
- The results are therefore in a similar range to the injectable Wegovy pen (2.4 mg)
Important to note: These figures come from controlled study conditions with close medical supervision. In everyday life, the actual result depends heavily on how consistently the instructions for use are followed and how the therapy is combined with diet and exercise habits.
Side effects and safety
The side effect profile of the tablet is similar to that of the injection, as both contain the same active ingredient. The most frequently reported side effects in the studies were:
- Nausea, especially during the dose escalation phase
- Diarrhea or constipation
- Vomiting and feelings of fullness
- Headaches and fatigue to a lesser extent
A difference from the injection: Because the tablet is taken orally, gastrointestinal complaints tend to occur slightly more frequently during the dose-escalation phase. Most side effects subside over time once the body has become accustomed to the substance.
As with any prescription medication: Therapy is carried out exclusively under medical supervision, with the doctor individually weighing whether the benefits and risks are in a good ratio in each case.
Who is the weight loss pill suitable for?
The EMA recommendation provides the Wegovy tablet for:
- Adults with obesity (BMI of 30 or higher)
- Adults with overweight (BMI of 27 or higher) and at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or sleep apnea
- The therapy is not suitable, among other things, for those with a history of medullary thyroid carcinoma, or in combination with other GLP-1 medications.
Prescription is always provided after an individual medical assessment and in combination with adjustments to diet and exercise. The tablet does not replace a healthy lifestyle, but supports it.
Weight loss pill or injection - what fits better?
Both dosage forms achieve a comparable effect with consistent use. The decision is therefore less a question of efficacy than a question of personal daily routine:
- Arguments for the tablet: no needles, no refrigeration required, discreet use possible on the go
- Arguments for the injection: only necessary once a week, no fasting required, no danger of forgetting to take it during daily stress
Those who fear needles or find an injection to be a hurdle gain a real alternative with the tablet. Those who prefer not to think about a tight time window every day, on the other hand, may find the weekly injection easier.
When is the weight loss pill coming to Germany?
On May 22, 2026, the CHMP recommended EU approval of the Wegovy tablet, the first oral GLP-1 therapy for weight loss in Europe. The formal decision by the European Commission is still pending at this time, but is generally considered a formality given a positive CHMP recommendation.
Following EU approval, national steps for Germany still need to follow, such as listing with the Federal Institute for Drugs and Medical Devices (BfArM) and inclusion in pharmaceutical wholesale. The sales launch in Germany is currently planned for August 2026. Until then, the injection remains the only available GLP-1 option in this country. There is no official information yet regarding price and possible health insurance reimbursement in Germany.
Frequently asked questions about the weight loss pill
Is the tablet stronger than the injection?
No. Despite the higher milligram number, the amount actually effective in the body is comparable; the higher dose merely compensates for the poorer absorption in the gastrointestinal tract.
Can I switch between the tablet and the injection?
Switching is generally possible, but should only be done in consultation with a doctor, as the dosage regimens differ.
Is the tablet suitable for everyone who wants to lose weight?
No. It is a prescription medication for defined medical indications (obesity or overweight with comorbidity), not a general diet aid.
Conclusion on the weight loss pill
The oral GLP-1 tablet is not a new substance, but a new dosage form of an already well-studied active ingredient. It expands the options for people who fear needles, but in return requires a very precise daily routine. Until it is available in Germany, there is time to discuss the most suitable form of therapy for your own situation with a doctor at your leisure.
Sources:
- Apotheken Umschau: Weight loss tablet with semaglutide awaiting EU approval
- GLP-1 Forum: Wegovy pill: EMA recommends first oral weight loss medication for Europe
- AJMC: FDA approves oral semaglutide as the first GLP-1 pill for weight loss
- Myvoy: Wegovy as a tablet: When is the pill coming to Germany?
- Apotheke Adhoc: Semaglutide tablet also available in Germany
- Biopharm: European Commission approves once-weekly Wegovy dose
